Hematopoiesis News Volume 5.02 | Jan 21 2014

C/EBPα Is Required for Long-Term Self-Renewal and Lineage Priming of Hematopoietic Stem Cells and for the Maintenance of Epigenetic Configurations in Multipotent Progenitors
Researchers report that C/EBPα serves to protect adult hematopoietic stem cells (HSCs) from apoptosis and to maintain their quiescent state. Consequently, deletion of Cebpa is associated with loss of self-renewal and HSC exhaustion. [PLoS Genet] Full Article

Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myeloid Leukemia (AML) Cells
Scientists demonstrated the sensitizing effects of the histone hyperacetylation inducing pan-histone deacetylase inhibitor panobinostat on human AML blast progenitor cells to the bromodomain and extra terminal protein antagonist JQ1. [Mol Cancer Ther] Abstract

Remodeling of Marrow Hematopoietic Stem and Progenitor Cells by Non-Self ST6Gal-1 Sialyltransferase
Scientists showed that extracellular ST6Gal-1 sialyltransferase, originating mostly from the liver and released into circulation, targets marrow hematopoietic stem and progenitor cells (HSPCs) and mediates the formation of cell surface α2,6-linked sialic acids on HSPCs, as assessed by binding to the specific lectins, Sambucus nigra and Polysporus squamosus and confirmed by mass spectrometry. [J Biol Chem] Abstract

An Anti-Apoptotic Molecule Anamorsin Is Essential for Both Development and/or Maintenance of Hematopoietic Stem Cells and Microenvironments to Support Fetal Liver Hematopoiesis
Investigators characterized the hematopoietic defects in Anamorsin-deficient (AM-/-) fetal livers. The AM-/- fetal liver displayed significantly reduced numbers of c-Kit+ Sca-1+ Lin- cells. [Exp Hematol] Abstract

Indirect Immune Recognition of Mouse Embryonic Stem Cell-Derived Hematopoietic Progenitors In Vitro
Scientists compared the developmental maturity and immunogenicity of embryonic stem cell (ESC)-derived hematopoietic progenitors generated via two methods: embryoid body formation and culture of ESCs with the OP9 bone marrow stromal cell line. [Exp Hematol] Abstract

CLINICAL RESEARCH

Teriparatide (PTH 1-34) Treatment Increases Peripheral Hematopoietic Stem Cells in Postmenopausal Women
Researchers studied the impact of long-term daily teriparatide (PTH 1-34) treatment on cells of the hematopoietic lineage in postmenopausal women. Twenty-three postmenopausal women at high risk of fracture received teriparatide 20 mcg SC daily for 24 months as part of a prospective longitudinal trial. [J Bone Miner Res] Abstract

Achieving Deeper Molecular Response Is Associated with a Better Clinical Outcome in Chronic Myeloid Leukemia Patients on Imatinib Frontline Therapy
Investigators evaluated the frequency of complete molecular response in imatinib de novo chronic-phase chronic myeloid leukemia patients, identified baseline and under-treatment predictive factors of complete molecular response in patients achieving complete cytogenetic response and assessed if complete molecular response is associated with a better outcome. [Haematologica] Abstract | Full Article

Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease in Childhood: A Single Center Experience of 50 Patients
Researchers report the outcome of 50 consecutive children with severe sickle cell disease that received hematopoietic stem cell transplantation in their unit between November 1988 and April 2013. [Br J Haematol] Abstract

Phase I/II Study of VELCADE®-BEAM (V-BEAM) and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Indolent Non-Hodgkin Lymphoma (NHL), Transformed, or Mantle Cell Lymphoma (MCL)
A Phase I/II trial was designed to evaluate the safety and activity of adding bortezomib to standard BEAM (BCNU, etoposide, cytarabine, melphalan) and ASCT. Eligible patients had relapsed/refractory indolent or transformed NHL or MCL that was relapsed/refractory or in first partial or complete remission. [Biol Blood Marrow Transplant] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

The HUB Foundation for Organoid Technology and STEMCELL Technologies Sign Agreement on the Manufacturing of Cell Culture Media for Organoids
The HUB Foundation for Organoid Technology announced that it has signed a licensing agreement with STEMCELL Technologies Inc. for the manufacturing and worldwide distribution of cell culture media for growing Organoids. Organoids are mini-organs grown in tissue culture from small pieces of tissue derived from patients with cancer and other diseases, and represent an exciting new tool for scientific research and drug discovery and validation. [STEMCELL Technologies Inc.] Press Release

From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the hematopoiesis research community.

Scientific Affairs Coordinator (American Society of Hematology)

Postdoctoral Position – Erythroid and Myeloid Differentiation of Hematopoietic Stem Cells (Imagine Institute)

Postdoctoral Associate – Hematopoietic Differentiation (Northwestern University Feinberg School of Medicine)

Postdoctoral Fellow – Mammalian Hematopoietic and Erythroid Development (Mount Sinai Medical Center)

Chief Medical Officer – Novel Therapeutics in Oncology and Autoimmune Disease (Immunomedics, Inc.)

Clinical MD – Clinical Development Program for Oncology and Autoimmune Diseases (Immunomedics, Inc.)

Postdoctoral Fellow – Molecular Basis of Clonal Evolution in Leukemia (Northwestern University)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.